Skip to content
Company Analysis

Mereo BioPharma Group plc MREO

A comprehensive view of key metrics, scores, and financial health for Mereo BioPharma Group plc

Overview of Mereo BioPharma Group plc

MREO NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Mereo BioPharma Group plc (MREO), is a Micro Cap company, in the Biotechnology industry, last closed at $0.31, about 0.0% overvalued vs fair value, -82.4% 1Y return, placing in the top 25% of its sector.
Metrics ROE -82.2% Gross Margin 73.4%
USD 0.31
0.26%
(Delayed)
• Vol 90d: 79.5%
52-Week Range
Market Cap
$51.75M
Enterprise Value
$15.53M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 82%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.mereobiopharma.com
HQ London
Employees 36
Fiscal year Dec 31

Next Events

Earnings Aug 11 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $0.31

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$41.0M
-41.3%%
Total Revenue
$500.0K
Net Income
$-41.9M
3.2%%
Operating Expense
$38.6M
-15.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
15.9 months
Fair

Limited runway, likely needs financing within a year

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Mereo BioPharma Group plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
30
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
26
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing MREO's balance between Growth (14.5%), Profitability (25.0%), and Safety (60.6%). Growth 14% Safety 61% Profitability 25%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

19th percentile vs peers
19
Key Signals
TSR -73.5% 19p
Strengths
  • Cash to Debt Ratio in top 20% of peers (202.93, 95th percentile)
  • Current Ratio in top 20% of peers (10.46, 84th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 19)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

80th percentile vs peers
81
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Mereo BioPharma Group plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.40
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000